Document Detail

Evaluation of external radiation exposure rate from radioiodine-treated hyperthyroid patients and radiation safety considerations.
MedLine Citation:
PMID:  8878129     Owner:  NLM     Status:  MEDLINE    
Hyperthyroid patients treated with radioiodine (131I) pose an external radiation risk to individuals who come into close contact with them. In order to determine changes in levels of external radiation with time in relation to the dose administered, 38 hyperthyroid patients being treated with 131I were evaluated Thyroid uptake, plasma T3, T4 and TSH levels were measured prior to treatment. Using a Geiger-Muller probe, levels of external radiation were measured at distances of 0.3, 0.6, 1.0 and 2.0 m from the patient -at the level at which the maximum activity was recorded -30 min, 1, 3, 7 and 10 days post-therapy. The patients were split into two groups. Group I comprised 22 patients treated with < or = 370 MBq 131I, 5 (23%) of whom registered > 0.46 mC kg-1 at a distance of 1.0 m 30 min post-therapy. Group II comprised 16 patients treated with > 370 MBq 131I, 13 (81%) of whom registered 0.46 mC kg-1 at a distance of 1.0 m one day post-therapy. At 3 days in Group I and 7 days in Group II, the estimated total radiation exposure rates were found to exceed the 1994 US Nuclear Regulatory Commission dose limits for children and pregnant women. Based on the results obtained, we present some guidelines intended to prevent the public from unnecessary radiation exposures.
M Demir; L Kabasakal; C Onsel
Related Documents :
3020879 - Thyroid function after postoperative radiation therapy in patients with breast cancer.
171899 - Human lymphocyte binding and deiodination of thyroid hormones in relation to thyroid fu...
6416819 - The suppression of tsh in the presence of the normal prl responses to trh out of 26 pat...
17060029 - Thyroid peroxidase and thyroglobulin auto-antibodies in patients with newly diagnosed o...
17121519 - Effect of thyroxine replacement on serum igf-i, igfbp-3 and the acid-labile subunit in ...
16430719 - Increase of interferon-gamma-inducible cxc chemokine cxcl10 serum levels in patients wi...
15991059 - Utility of 2-fluoro-2-deoxy-d-glucose positron emission tomography in managing patients...
3898689 - Aminoglutethimide and metyrapone in the management of cushing's syndrome.
6229559 - Frusemide: a safe diuretic during lithium therapy?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  17     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  1996 Aug 
Date Detail:
Created Date:  1997-02-13     Completed Date:  1997-02-13     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  692-5     Citation Subset:  IM    
Department of Nuclear Medicine, Cerrahpaşa Medical Faculty, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Graves Disease / metabolism,  radiotherapy*
Iodine Radioisotopes / adverse effects*,  pharmacokinetics,  therapeutic use
Middle Aged
Radiation Protection*
Radiotherapy Dosage
Time Factors
Reg. No./Substance:
0/Iodine Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body sc...
Next Document:  99Tcm-HMPAO brain SPET in patients with pseudotumour cerebri.